Abstract: A first object of the invention is galactosaminogalactan comprising ?1-4 linked galactose, ?1-4 linked N-acetylgalactosamine, and optionally ?1-4 linked galactosamine, for use in the treatment of at least one inflammatory disease. Another object of the invention is a pharmaceutical composition comprising a galactosaminogalactan comprising ?1-4 linked galactose, ?1-4 linked N-acetylgalactosamine, and optionally ?1-4 linked galactosamine, as defined herein, and optionally a pharmaceutically acceptable carrier. Another object of the invention is a pharmaceutical composition according to the invention, for use in the treatment of at least one inflammatory disease. Another object of the invention is an inhibitor of IL-1RA for use in the treatment of human fungal diseases. Another object of the invention is a pharmaceutical composition comprising an inhibitor of IL-1RA, and optionally a pharmaceutically acceptable carrier.

Abstract: Defibrinated and lyophilized placental cells are prepared by taking the foetomaternal placenta of a ewe killed at the end of the fourth month of gestation, breaking the placenta into fragments, immediately submerging the fragments in Ringer's solution to wash away traces of blood, finely dividing the fragments, placing them in 5% aqueous trypsinated solution, permitting tryptic digestion with stirring, separating the placental cells by filtering, washing the cells in refrigerated Hanks solution, centrifuging in a low temperature centrifuge, suspending the base obtained in the centrifuging step in a minimum of survival liquid and lyophilizing the suspension until constant weight is obtained. The cells obtained are used in the external treatment of ulcers and first and second degree burns.